Quarry LP’s Regencell Bioscience RGC Stock Holding History

Quarry LP’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-468	Closed	-$9.8K	–	2115
2025 Q4	$9.8K	Buy	+468	New	+$7.61K	﹤0.01%	1417

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $13.9B AUM 53.47% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Quarry LP's RGC Position: Q1 2026 in Review

Quarry LP sold out of Regencell Bioscience (RGC) in Q1 2026, closing a stake of 468 shares — an estimated $9.8K sold.

Quarry LP first reported a position in RGC in Q4 2025 and held it in 1 quarter. The position peaked at $9.8K in Q4 2025. 33 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

Quarry LP reported no remaining Regencell Bioscience position as of Q1 2026 after selling out during the quarter.
Quarry LP sold 468 Regencell Bioscience shares in Q1 2026, an estimated $9.8K.
Quarry LP first reported a position in Regencell Bioscience in Q4 2025 and held it in 1 quarter.
Quarry LP's Regencell Bioscience position peaked at $9.8K in Q4 2025.
33 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Quarry LP's 13F filing for Q1 2026, filed 15 May 2026.